CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
conjugated estrogens +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00004650
NCT00004650Phase 3Completed
CompareCT.gov

Phase III Randomized Study of the Effect of Postmenopausal Estrogen Replacement Therapy on Alveolar Bone Loss

National Institute of Dental and Craniofacial Research (NIDCR)·interventional·Posted Feb 25, 2000·Updated Jun 24, 2005

In Brief

A Phase 3 clinical trial evaluating conjugated estrogens and Medroxyprogesterone for Osteoporosis. Completed.

Detailed Summary

OBJECTIVES: I. Quantify periodontal alveolar bone loss rates in postmenopausal women. II. Evaluate the effects of estrogen on alveolar bone loss rates in these patients. III. Determine whether changes in periodontal bone mass relate to bone mass changes in other skeletal sites in these patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
Countries--
CollaboratorsWashington University School of Medicine

Timeline

Phase 3CompletedFinished
19931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 25, 2000
Enrollment StartAug 1, 1993
TodayJul 2, 2026
Posted 26.4 years ago

Interventions

conjugated estrogensdrug

Medroxyprogesteronedrug